Quest Diagnostics Inc. (DGX) is a publicly traded Healthcare sector company. As of May 21, 2026, DGX trades at $193.75 with a market cap of $21.01B and a P/E ratio of 21.18. DGX moved +2.02% today. Year to date, DGX is +11.68%; over the trailing twelve months it is +8.70%. Its 52-week range spans $146.17 to $213.50. Analyst consensus is buy with an average price target of $220.50. Rallies surfaces DGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Quest Diagnostics jumps after Q1 beat and raised 2026 revenue, EPS guidance: Quest Diagnostics shares are higher as investors react to the company’s Q1 2026 results and a raised full‑year outlook. Quest reported adjusted EPS of $2.50 on roughly $2.90B in revenue and lifted 2026 revenue and adjusted EPS guidance ranges.
| Metric | Value |
|---|---|
| Price | $193.75 |
| Market Cap | $21.01B |
| P/E Ratio | 21.18 |
| EPS | $9.17 |
| Dividend Yield | 0.86% |
| 52-Week High | $213.50 |
| 52-Week Low | $146.17 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $11.28B |
| Net Income | $1.07B |
| Gross Margin | 33.20% |
9 analysts cover DGX: 0 strong buy, 4 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $220.50.